Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

221.50DKK
13 Dec 2017
Change (% chg)

kr.-9.50 (-4.11%)
Prev Close
kr.231.00
Open
kr.228.50
Day's High
kr.229.50
Day's Low
kr.221.50
Volume
229,175
Avg. Vol
309,067
52-wk High
kr.444.00
52-wk Low
kr.183.00

Chart for

About

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate... (more)

Overall

Beta: 1.30
Market Cap(Mil.): kr.7,448.61
Shares Outstanding(Mil.): 32.25
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.96 15.25
EPS (TTM): -- -- --
ROI: -- 15.07 33.27
ROE: -- 16.58 16.35

BRIEF-Bavarian Nordic Q3 EBIT at DKK 432 million

* Q3 EBIT DKK 432.0 ‍​ MILLION VERSUS LOSS DKK 124.8 MILLION YEAR AGO

Nov 08 2017

SGS and Bavarian Nordic developing challenge strain to combat respiratory virus​

ZURICH SGS and Bavarian Nordic are teaming up to develop a virus challenge strain to combat a common respiratory illness.

Oct 12 2017

SGS and Bavarian Nordic developing challenge strain to combat respiratory virus​

ZURICH, Oct 12 SGS and Bavarian Nordic are teaming up to develop a virus challenge strain to combat a common respiratory illness.

Oct 12 2017

BRIEF-Bavarian Nordic wins big smallpox vaccine order for U.S. government

* SECURES CONTRACT AWARD FOR SUPPLY OF FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE TO THE U.S. GOVERNMENT

Sep 28 2017

BRIEF-Bavarian Nordic provides update on its RSV vaccine

* REG-BAVARIAN NORDIC PROVIDES UPDATE ON ITS UNIVERSAL RSV VACCINE

Sep 21 2017

BRIEF-Bavarian Nordic says independent Data Monitoring Committee determined continuation of Phase 3 prospect study of Prostvac is futile

* Independent Data Monitoring Committee recommends discontinuation of Bavarian Nordic's Phase 3 study of Prostvac in metastatic prostate cancer

Sep 14 2017

Bavarian Nordic says first milestone payment under J&J deal could be in 2019

COPENHAGEN Danish biotech company Bavarian Nordic expects to get its first milestone payment under a deal with Janssen Pharmaceuticals in 2019, if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year, a company executive said.

Aug 25 2017

UPDATE 1-Bavarian Nordic says first milestone payment under J&J deal could be in 2019

* But may take on some risk in respiratory diseases (adds detail on RSV, Prostvac and partnerships)

Aug 25 2017

Bavarian Nordic says first milestone payment under new J&J deal could be in 2019

COPENHAGEN, Aug 25 Danish biotech company Bavarian Nordic expects to get a first milestone payment under a new deal with Janssen Pharmaceuticals in 2019, if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year, a company executive said.

Aug 25 2017

BRIEF-Bavarian Q2 EBIT at DKK 102.3 million

* Q2 REVENUE DKK 397.3‍​ MILLION VERSUS DKK 116.6 MILLION YEAR AGO

Aug 25 2017

Earnings vs. Estimates